On Thursday, Royalty Pharma plc (RPRX) stock saw a decline, ending the day at $25.58 which represents a decrease of $-0.27 or -1.04% from the prior close of $25.85. The stock opened at $25.9 and ...

The market shrugged off Royalty Pharma plc's ( NASDAQ:RPRX ) solid earnings report. We think that investors might ...

On November 6, 2024, Royalty Pharma PLC (NASDAQ:RPRX), the industry-leading acquirer of biopharmaceutical royalties, filed its 10-Q report, revealing the latest financials and strategic insights.

On Wednesday, Royalty Pharma plc (RPRX) stock saw a decline, ending the day at $26.64 which represents a decrease of $-0.90 or -3.27% from the prior close of $27.54. The stock opened at $28.13 and ...

Summit Global Investments acquired a new stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) during the third quarter, ...

Atria Investments Inc trimmed its stake in Royalty Pharma plc (NASDAQ:RPRX – Free Report) by 15.0% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and ...

Q3 2024 Earnings Call Transcript November 6, 2024 Royalty Pharma plc misses on earnings expectations. Reported EPS is $0.918 ...

On November 6, 2024, Royalty Pharma PLC (NASDAQ:RPRX), the industry-leading acquirer of biopharmaceutical royalties, filed its 10-Q report, revealing the latest financials and str ...

In a report released on November 7, Geoff Meacham from Citi maintained a Buy rating on Royalty Pharma (RPRX – Research Report). The company’s shares closed yesterday at $26.21. According to TipRanks, ...

Royalty Pharma's Q3 results show growth driven by strong portfolio performance and acquisitions. See why we recommend a buy ...